Company news

Poolbeg Pharma PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

H.C. Wainwright Global Investment Conference

August 27, 2024

Poolbeg Pharma plc - Voluntary Delisting from OTCQB Market

July 29, 2024

Voluntary Delisting from OTCQB Market

July 26, 2024

Change of Registered Address

July 2, 2024

Result of AGM

June 17, 2024

Poolbeg Pharma plc - Annual Report and AGM Notice

May 10, 2024

Annual Report & AGM Notice

May 9, 2024

Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office

May 8, 2024

Significant POLB 001 Patent Granted in USA

May 1, 2024

Appointment of Joint Broker

April 30, 2024

Option Agreement to Acquire Orphan Drug Candidate

April 30, 2024

Results for the year ended 31 December 2023

April 30, 2024

TR-1: Notification of major holdings

April 29, 2024

POLB 001 US Patent Update

March 20, 2024

Poolbeg Pharma plc - Director Share Purchase

February 23, 2024

Director Share Purchase

February 19, 2024

Board Role Change and Launch of EIP

February 15, 2024

Market Opportunity for POLB 001 for CRS

February 12, 2024

Poolbeg Pharma plc - Further Data Confirms POLB 001's Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome

January 18, 2024

Further data shows POLB001 potential in cancer CRS

January 17, 2024

RSV AI Drug Candidate Analysis Update

December 20, 2023

Poolbeg Pharma plc - POLB 001 Data Presented at ASH

December 12, 2023

POLB 001 Data Presented at ASH

December 11, 2023

Directorate Change

November 30, 2023

Poolbeg Pharma plc - Immunomodulator II patent granted in Japan

November 22, 2023

Immunomodulator II patent granted in Japan

November 21, 2023

Poolbeg Pharma plc - POLB 001 LPS Challenge Trial Data to be presented at IUIS

November 17, 2023

POLB 001 LPS Trial Data to be Presented at IUIS

November 16, 2023

Former Amryt Pharma Leadership Team join Poolbeg

November 9, 2023

POLB001 Data to be Presented at ASH Annual Meeting

November 3, 2023

POLB 001 Oncology Programme Update Meeting

November 1, 2023

SAB Endorses Influenza Drug Targets

October 26, 2023

Poolbeg Partners with a Nasdaq-Listed Biopharma

October 17, 2023

Favourable Conclusion of Patent Opposition

September 29, 2023

Immunomodulator I Patent Portfolio Strengthened

September 20, 2023

Immunomodulator I Patent Opposition Withdrawal

September 19, 2023

Interim results for the six months to 30 June 2023

September 13, 2023

AI led programme identifies influenza drug targets

June 29, 2023

Oral Vaccine Programme Moves Forward

June 22, 2023

Board Appointment

May 24, 2023

Results of Annual General Meeting

May 11, 2023

Results for the year ended 31 December 2022

March 30, 2023

POLB 001 patent portfolio strengthened

March 8, 2023

Second Price Monitoring Extn

March 2, 2023

Price Monitoring Extension

March 2, 2023

Positive Results POLB001 LPS Human Challenge Trial

March 2, 2023

Strategic expansion of POLB 001 into oncology

January 16, 2023

Positive Initial Data Analysis in POLB 001 Trial

January 9, 2023

Poolbeg Pharma identifies new RSV drug candidates

December 22, 2022

Poolbeg identifies novel RSV drug candidates

December 21, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 8 decks. Every deck is listed under its year.